Avoid common mistakes on your manuscript.
Correction to: Drugs (2023) 83:1635–1643 https://doi.org/10.1007/s40265-023-01962-w
In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth sentence, which currently reads:
In this study, a single subcutaneous injection of motixafortide (part 1: 1 mg/kg; part 2: 1.25 mg/kg) resulted in the collection of ≥ 2 × 106 CD34+ cells/kg within two leukapheresis procedures (primary endpoint) in 11 (85%) of 13 adult allogenic donors in part 1 and 11 (100%) of 11 of 13 adult allogenic donors in part 2. The collection of ≥ 2 × 106 CD34+ cells/kg in one leukapheresis procedure occurred in 11 (85%) of 13 allogenic donors and 8 (73%) of 11 allogeneic donors, respectively.
Should read:
In this study, a single subcutaneous injection of motixafortide (part 1: 1 mg/kg; part 2: 1.25 mg/kg) resulted in the collection of ≥ 2 × 106 CD34+ cells/kg within two leukapheresis procedures (primary endpoint) in 11 (85%) of 13 adult allogenic donors in part 1 and 11 (100%) of 11 adult allogenic donors in part 2. The collection of ≥ 2 × 106 CD34+ cells/kg in one leukapheresis procedure occurred in 11 (85%) of 13 allogenic donors and 8 (73%) of 11 allogeneic donors, respectively.
The original PDF version of the article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoy, S.M. Correction to: Motixafortide: First Approval. Drugs 83, 1737 (2023). https://doi.org/10.1007/s40265-023-01984-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01984-4